A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Aim Cetuximab and panitumumab are common antibodies against epidermal growth factor receptor (EGFR) that can be used in combination with chemotherapy for the treatment of metastatic colorectal cancer (mCRC). Although these two drugs are considered to be very similar, differences in the efficacy and safety of cetuximab and panitumumab are still unclear. We conducted this meta-analysis to explore the effects and adverse reactions of cetuximab and panitumumab in the treatment of mCRC.Methods We searched PubMed, the Cochrane Library, Embase, Web of Science, China national knowledge infrastructure (CNKI) and WanFang databases to identify records related to the efficacy and safety of cetuximab and panitumumab in the treatment of mCRC. The search terms were “cetuximab,” “panitumumab,” and “colorectal cancer.” The deadline of searching was April 2022. Review manager 5.4 software was used to perform the statistical analysis for this meta-analysis. Pooled hazard ratio (HR) with 95% confidence intervals (CI) were calculated to evaluate the overall survival (OS) and progression free survival (PFS) of cetuximab and panitumumab in the treatment of mCRC.Results There was no significant difference in OS, PFS, and response rate (RR) between cetuximab arm and panitumumab arm (OS: HR = 0.91, 95% CI = 0.81–1.03, p = .14; PFS: HR = 0.92, 95% CI = 0.83–1.02, p = .11; RR: OR = 1.22, 95% CI = 0.96–1.61, p = .14). We also did not observe any statistical difference between both arms in incidence of acneiform rash, severe acneiform rash, diarrhea, and severe diarrhea (acneiform rash: OR = 1.09, 95% CI = 0.84–1.42, p = .51; severe acneiform rash: OR = 1.50, 95% CI = 0.80–2.81, p = .21; diarrhea: OR = 1.08, 95% CI = 0.82–1.42, p = .58; severe diarrhea: OR = 0.90, 95% CI = 0.44–1.84, p = .77). The incidence of paronychia was decreased in the panitumumab arm, but that of hypomagnesemia and severe hypomagnesemia were decreased in the cetuximab arm. (paronychia: OR = 0.74, 95% CI = 0.55–1.00, p = .05; hypomagnesemia: OR = 1.85, 95% CI =1.41–2.41, p < .00001; severe hypomagnesemia: OR = 2.66, 95% CI = 1.52–4.67, p = .0006).Conclusion There was no significant difference in OS, PFS and RR between the cetuximab arm and panitumumab arm in the treatment of mCRC. For adverse reactions, the incidence of paronychia was decreased in the panitumumab arm, and the incidence of hypomagnesemia was deceased in the cetuximab arm.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For decades, targeted anti-EGFR therapy has proven highly successful in treating mCRC for which neither activating RAS or BRAF mutations were detected [30].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [30]
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
null (2016) · Philosophy Study · doi:10.17265/2159-5313/2016.09.003 · Cited by 28,317
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164 · cited 1×
“This meta-analysis was performed following the guidelines of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement [15,16].”
MethodSiegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review
Biller, L. H., & Schrag, D. (2021) · JAMA · doi:10.1001/jama.2021.0106 · Cited by 2,604
Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A., Schrag, D., Greene, C., O'Neil, B. H., Atkins, J. N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7105 · Cited by 898
Allegra, C. J., Rumble, R. B., Hamilton, S. R., Mangu, P. B., Roach, N., Hantel, A., & Schilsky, R. L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9674 · Cited by 264 · cited 1×
“that the benefits from cetuximab and panitumumab are restricted to patients whose tumors did not contain mutations in RAS genes [11].”
BackgroundKim, M. S., An, M. H., Kim, W. J., & Hwang, T.-H. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003501 · Cited by 246
Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
García-Foncillas, J., Sunakawa, Y., Aderka, D., Wainberg, Z., Ronga, P., Witzler, P., & Stintzing, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00849 · Cited by 201
Li, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa026 · Cited by 119 · cited 1×
“As highly effective antibodies targeting EGFR, cetuximab and panitumumab have better clinical activity in the patients with mCRC [7].”
Background
Research works printed but not linked: 4
- Krawczyk PA, 2014, Contemp Oncol (Pozn), 18, 7
- Merck KGaA Press Release. 2017. Available from: https://www.ots.at/presseaussendung/OTE_20170302_OTE0001/nice-expands-positive-recommendation-for-erbitux-as-fifirst-line-treatment-for-ras-wild-type-mcrc (accessed March 2018).
- Liu T, 2020, Evid Based Complement Alternat Med, 2020, 1
- Yamaguchi T, 2016, Anticancer Res, 36, 3531
Cited by
Colorectal cancer: Recent advances in management and treatment
Fadlallah, H., El Masri, J., Fakhereddine, H., Youssef, J., Chemaly, C., Doughan, S., & Abou-Kheir, W. (2024) · World Journal of Clinical Oncology · doi:10.5306/wjco.v15.i9.1136 · Cited by 169
“However, panitumumab was shown to have a reduced incidence of paronychia, while cetuximab had a decreased risk of hypomagnesemia[108].”
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“Cetuximab and panitumumab treatment results in similar Although not common, the use of these mAbs may be associated with adverse reactions with decreased paronychia (nail infection) observed with panitumumab [30]. survival benefit.”
BackgroundImmunotherapy in microsatellite-stable colorectal cancer: Strategies to overcome resistance
Chen, E., & Zhou, W. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104775 · Cited by 73
A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy
Justiz-Vaillant, A. A., Pandit, B. R., Unakal, C. G., Vuma, S., & Akpaka, P. E. (2025) · Antibodies · doi:10.3390/antib14020035 · Cited by 39
Colorectal Cancer: Therapeutic Approaches and Their Complications
Adebayo, A. S., Adeleke, A., Adesina, S. K., Agbaje, K. O., & Olajubutu, O. (2025) · Biomedicines · doi:10.3390/biomedicines13071646 · Cited by 32
“Additionally, cutaneous toxicity is almost universal in patients receiving panitumumab, which may be attributed to its higher affinity for the receptor [208,209].”
Metadata
- Authors
- Liu, T., Jiang, S., Teng, X., Zhong, L., Liu, M., Jin, Y., & Dong, M.
- Affiliations
- Third Affiliated Hospital of Harbin Medical University (CN)
- Corresponding author
- Dong, Mei
- Venue
- Immunopharmacology and Immunotoxicology
- Publisher
- Informa UK Limited
- Published
- 2022-08-18
- Volume
- 45
- Issue
- 1
- Pages
- 1-9
- ISSN
- 0892-3973 (ISSN-L)
- 1532-2513
- OpenAlex
- W4290803826
- Cited by
- 17
- References
- 18
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 4 · 2023: 3
- FWCI
- 0.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Immunopharmacology and Immunotoxicology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- panitumumab, cetuximab, metastatic colorectal cancer, KRAS wild-type, EGFR inhibitors, anti-EGFR antibody therapy, overall survival, progression-free survival, acneiform rash, diarrhea, drug safety, treatment efficacy, combination chemotherapy, response rate, time to progression, time to response, treatment response time
- MeSH terms
- Cetuximab, Panitumumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Exanthema, Humans, Paronychia, Rectal Neoplasms, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1080/08923973.2022.2112222
- The paper
- Liu, T., Jiang, S., Teng, X., Zhong, L., Liu, M., Jin, Y., & Dong, M. (2023). A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Immunopharmacology and Immunotoxicology. https://doi.org/10.1080/08923973.2022.2112222
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.